COHEN & STEERS INC (CNS) Stock Fundamental Analysis
NYSE:CNS - New York Stock Exchange, Inc. - US19247A1007 - Common Stock - Currency: USD
Overall CNS gets a fundamental rating of 6 out of 10. We evaluated CNS against 232 industry peers in the Capital Markets industry. While CNS has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, CNS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
In the past year CNS has reported a negative cash flow from operations.
CNS had positive earnings in each of the past 5 years.
In the past 5 years CNS always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 18.81%, CNS belongs to the best of the industry, outperforming 98.28% of the companies in the same industry.
CNS's Return On Equity of 30.93% is amongst the best of the industry. CNS outperforms 95.26% of its industry peers.
CNS's Return On Invested Capital of 20.82% is amongst the best of the industry. CNS outperforms 96.98% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.85%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(20.82%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.81% | ||
| ROE | 30.93% | ||
| ROIC | 20.82% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
CNS has a better Profit Margin (29.68%) than 73.71% of its industry peers.
CNS's Profit Margin has declined in the last couple of years.
CNS's Operating Margin of 33.60% is fine compared to the rest of the industry. CNS outperforms 60.34% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS has a Gross Margin of 88.86%. This is amongst the best in the industry. CNS outperforms 92.24% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.6% | ||
| PM (TTM) | 29.68% | ||
| GM | 88.86% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
The number of shares outstanding for CNS has been increased compared to 1 year ago.
CNS has more shares outstanding than it did 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.28 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS has a Altman-Z score of 8.28. This is amongst the best in the industry. CNS outperforms 92.67% of its industry peers.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.28 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.80. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.80, CNS is not doing good in the industry: 66.81% of the companies in the same industry are doing better.
A Quick Ratio of 0.80 indicates that CNS may have some problems paying its short term obligations.
CNS's Quick ratio of 0.80 is on the low side compared to the rest of the industry. CNS is outperformed by 66.38% of its industry peers.
The current and quick ratio evaluation for CNS is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
CNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.58%.
CNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.50% yearly.
The Revenue has grown by 8.82% in the past year. This is quite good.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
Revenue 1Y (TTM)8.82%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
3.2 Future
The Earnings Per Share is expected to grow by 10.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.94% on average over the next years.
EPS Next Y6.69%
EPS Next 2Y10.54%
EPS Next 3Y10.74%
EPS Next 5Y10.36%
Revenue Next Year5%
Revenue Next 2Y8.63%
Revenue Next 3Y7.61%
Revenue Next 5Y7.94%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.66 indicates a quite expensive valuation of CNS.
Based on the Price/Earnings ratio, CNS is valued a bit more expensive than 65.95% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.91. CNS is around the same levels.
With a Price/Forward Earnings ratio of 21.36, CNS is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.46, CNS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.66 | ||
| Fwd PE | 21.36 |
4.2 Price Multiples
CNS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CNS is cheaper than 71.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.4 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CNS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.84
PEG (5Y)10.28
EPS Next 2Y10.54%
EPS Next 3Y10.74%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.33%, CNS has a reasonable but not impressive dividend return.
CNS's Dividend Yield is comparable with the industry average which is at 8.07.
CNS's Dividend Yield is a higher than the S&P500 average which is at 2.43.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.33% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
77.43% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP77.43%
EPS Next 2Y10.54%
EPS Next 3Y10.74%
NYSE:CNS (6/25/2025, 12:11:39 PM)
76.48
-0.49 (-0.64%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners59.52%
Inst Owner Change0.29%
Ins Owners22.52%
Ins Owner Change0.64%
Market Cap3.90B
Analysts76.67
Price Target87.72 (14.7%)
Short Float %6.47%
Short Ratio9.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.33% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP77.43%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.32%
Min EPS beat(2)-2.29%
Max EPS beat(2)-0.35%
EPS beat(4)1
Avg EPS beat(4)-1.1%
Min EPS beat(4)-2.29%
Max EPS beat(4)0.49%
EPS beat(8)2
Avg EPS beat(8)-0.99%
EPS beat(12)6
Avg EPS beat(12)0.97%
EPS beat(16)10
Avg EPS beat(16)3.04%
Revenue beat(2)1
Avg Revenue beat(2)-4.71%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.78%
PT rev (3m)-8.51%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)-1.94%
EPS NY rev (1m)2.15%
EPS NY rev (3m)-1.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.66 | ||
| Fwd PE | 21.36 | ||
| P/S | 7.37 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.68 | ||
| P/tB | 7.98 | ||
| EV/EBITDA | 20.4 |
EPS(TTM)2.98
EY3.9%
EPS(NY)3.58
Fwd EY4.68%
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS10.38
BVpS9.96
TBVpS9.58
PEG (NY)3.84
PEG (5Y)10.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.81% | ||
| ROE | 30.93% | ||
| ROCE | 27.12% | ||
| ROIC | 20.82% | ||
| ROICexc | 23.12% | ||
| ROICexgc | 25.32% | ||
| OM | 33.6% | ||
| PM (TTM) | 29.68% | ||
| GM | 88.86% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexcg growth 3Y-36.94%
ROICexcg growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 74.13% | ||
| Cap/Sales | 1.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 8.28 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)7.58%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%7.14%
EPS Next Y6.69%
EPS Next 2Y10.54%
EPS Next 3Y10.74%
EPS Next 5Y10.36%
Revenue 1Y (TTM)8.82%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%9.58%
Revenue Next Year5%
Revenue Next 2Y8.63%
Revenue Next 3Y7.61%
Revenue Next 5Y7.94%
EBIT growth 1Y11.24%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year16.8%
EBIT Next 3Y17.3%
EBIT Next 5Y16.09%
FCF growth 1Y-117.6%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-111.18%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%